METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against resistant cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors o…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase: PHASE1 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC